Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Esten N Vandsemb; Tae Kon Kim; Amer M Zeidan

doi:10.1002/cncr.32042

Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Cancer. 2019 May 1;125(9):1410-1413. doi: 10.1002/cncr.32042. Epub 2019 Mar 12.

Authors

Esten N Vandsemb^{1

2

3}, Tae Kon Kim¹, Amer M Zeidan¹

Affiliations

¹ Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
² Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
³ Clinic of Laboratory Medicine, St Olav's Hospital, Trondheim, Norway.

Abstract

T cells in the bone marrow from patients with acute myeloid leukemia have increased expression of several immune checkpoint molecules. Can this knowledge be translated to novel therapeutic strategies?

Keywords: AML; acute myeloid leukemia; bone marrow; immune checkpoint blockade; immunotherapy.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bone Marrow*
Humans
Leukemia, Myeloid, Acute*
Ligands
T-Lymphocyte Subsets

Substances

Ligands

Abstract

Publication types

MeSH terms

Substances

Grants and funding